Tumor
of the anterior mediastinum, which occurs in the epithelial cells of the
thymus, is known as thymoma cancer. It is one of the rare leading causes of
cancer death, but the appropriate cause of this cancer is not known. The
researchers develop advanced immunotherapeutic cancer agents such as monoclonal
antibodies, therapeutic vaccines, kinase inhibitor and much more to treat this
tumor.
This
tumor is classified into five types that involve Type A, Type B1, Type B2, Type
B3, and Type C.
Type
A thymoma accounts for approximately 4% to 7% of all cases of this tumor, and
is also known as spindle cell thymoma or medullar thymoma.
Type
B1 thymoma represents about 9% to 20% of all tumors related to thymoma, and is
also known as lymphocytic thymoma, and predominantly cortical thymoma. This
type of tumor has a high concentration of lymphocytes, even the cells of the
thymus appear in normal condition.
 |
| www.gapsos.com |
Type
B2 thymoma has a high concentration of lymphocytes, are similar to the type B1
thymoma. T cells of the thymus do not appear as normal, and it is also known as
polygonal cell thymoma and cortical thymoma. It represents about 20% to 36% of
all tumor related to thymoma.
Type
B3 thymoma is also known as squamous thymoma, atypical thymoma, and epithelial
thymoma. It represents about 10% to 14% of thymoma tumor. This type of tumor
has few lymphocytes, and the cells of the thymus, which is looks like to normal
cells.
Type
C thymoma is very aggressive. The cells in a thymic carcinoma do not look like
normal cells of the thymus. It is also known as thymiccarcinoma; it may start
from a pre-existing thymoma that has converted into a more aggressive tumor.
This type of thymoma is an advanced form of this tumor.
In
immunotherapy, there are Monoclonal Antibodies (MABs) and kinase inhibitors are
used for the treatment of this tumor, but there is no single drug has approval
by United States Food and Drug Administration (U.S. FDA). However, many drugs,
including Cetuximab, Cixutumumab,
Saracatinib, and Sunitinib are under various
phases such as phase 1, phase 2, phase 3, and phase 4 of the clinical trials
for FDA approval.
Global
Allied Pharmaceuticals (GAP) is one of the leading supportive care units for
chronic disease like cancer. GAP has an expert team for immunotherapy and
immune combination therapy. Our experts provide all suitable services and
treatments to cancer patient, according to stage of disease.
For
more information kindly visit us at www.gapsos.com
No comments:
Post a Comment